By: IPP Bureau
Last updated : November 10, 2025 11:15 am
Venus Remedies now has 29 active product approvals in Vietnam alone
Venus Remedies Limited, one of the world’s top ten fixed-dosage injectable manufacturers, has announced the expansion of its export portfolio in the ASEAN region following new marketing authorisations for Methotrexate, Cefuroxime, and Irinotecan in Vietnam. These approvals strengthen India’s position as a trusted supplier of advanced pharmaceuticals across Southeast Asia, where Venus Remedies already holds more than 374 marketing authorisations.
With these new additions, Venus Remedies now has 29 active product approvals in Vietnam alone, underscoring its growing presence in one of the region’s most dynamic pharmaceutical markets. The approvals reinforce the company’s commitment to enhancing access to high-quality critical care injectables and supporting India’s vision of being a dependable global healthcare partner.
Commenting on the development, Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, said,
“This expansion aligns with our mission to democratize access to advanced critical care therapies across emerging markets. Southeast Asia continues to be a strategic focus area for Venus Remedies, and we aim to strengthen our presence through sustained portfolio diversification and long-term collaborations.”
Vietnam, India’s 15th largest trading partner and one of its top four pharmaceutical export destinations in Southeast Asia, has witnessed steady growth in bilateral pharmaceutical trade over the past five years. This growth is driven by rising demand for complex generics, affordable oncology, and antimicrobial therapies. The broader ASEAN pharmaceutical market is projected to reach USD 63.5 billion by 2029, highlighting its importance in India’s global trade strategy.
Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, added, “With these approvals, we reaffirm our commitment to healthcare providers and patients in Vietnam. Each regulatory milestone strengthens our resolve to build resilient supply chains and foster meaningful collaborations that elevate care standards across borders.”
The company’s continued expansion across Southeast Asia reflects India’s growing reputation as a reliable pharmaceutical hub. As these new authorisations come into effect, Venus Remedies remains focused on sustainable growth, regulatory excellence, and equitable access to essential medicines across emerging markets.